Background Information on Targeted Therapies in Breast Cancer

Panelists discuss how advancements in understanding HER2 expression have transformed the therapeutic landscape of breast cancer. The discussion highlights that HER2 amplification, historically seen as an aggressive disease marker, now represents a key therapeutic target, leading to markedly improved outcomes.

They examine the emergence of the HER2-low category—a newly recognized subset identified through refined IHCimmunohistochemistry and ISHin situ hybridization criteria—and emphasize its diagnostic nuances and implications for treatment eligibility.

The experts compare historical classifications of HER2 status with contemporary interpretations shaped by recent trials and regulatory updates. The session underscores how better biomarker stratification enhances precision medicine approaches and broadens treatment access for patients previously categorized as HER2-negative.